Vedolizumab manufacturers
- Vedolizumab
-
- $198.00
-
2026-07-10
- CAS:943609-66-3
- Purity: 98.00%
- Supply Ability: 10g
|
| | Vedolizumab Basic information |
| Product Name: | Vedolizumab | | Synonyms: | Vedolizumab;Vedolizumab USP/EP/BP;Research Grade Vedolizumab(DHC98802);Vedolizumab (anti-α4β7-integrin);Research Grade Vedolizumab;Vedolizumab 62.6mg/ml | | CAS: | 943609-66-3 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Vedolizumab Structure]() |
| | Vedolizumab Chemical Properties |
| storage temp. | Store at -80°C | | solubility | Soluble in DMSO | | form | Solid | | color | White to off-white |
| | Vedolizumab Usage And Synthesis |
| Uses | Vedolizumab is a humanized IgG1 monoclonal antibody that targets the α4β7 integrin for the treatment of ulcerative colitis and Crohn's disease. | | Clinical Use | Monoclonal antibody:
Treatment of ulcerative colitis and Crohn’s disease | | in vivo | Blockade of α4β7 receptors on T-lymphocytes has been shown to occur for several weeks after a single dose of vedolizumab. The drug concentration following the infusion has been shown to be dose related with a mean maximum concentration of 12.5 μg/mL in those receiving 0.5 mg/kg of vedolizumab and 52.0 μg/mL in those receiving 2 mg/kg. The serum half-life of these two doses is 9-12 days respectively and saturation of α4β7 receptors on T-lymphocytes is >90% at both 4-6 weeks following infusion. In a dose ranging study, the serum drug concentrations increase with increasing dose and when regular induction infusions are used (on day 1, 15, 29 and 85), the serum half-life is between 15 and 22 days across all groups[1]. | | Drug interactions | Potentially hazardous interactions with other drugs
Live vaccines: risk of generalised infections - avoid. | | Metabolism | The expected consequence of metabolism is proteolytic degradation to small peptides and individual amino acids, and receptor-mediated clearance. The exact elimination route of vedolizumab is unknown although renal clearance is expected to be negligible. | | References | [1] Soler D, et al. The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrintherapeutic antibody in development for inflammatory bowel diseases. J Pharmacol Exp Ther. 2009 Sep;330(3):864-75. DOI:10.1124/jpet.109.153973
[2] Singh H, et al. Vedolizumab: A novel anti-integrin drug for treatment of inflammatory bowel disease. J Nat Sci Biol Med. 2016 Jan-Jun;7(1):4-9. DOI:10.4103/0976-9668.175016 |
| | Vedolizumab Preparation Products And Raw materials |
|